Aldevron, a Danaher Corporation company, in collaboration with Integrated DNA Technologies, has successfully manufactured the world's first mRNA-based personalized CRISPR therapy. This groundbreaking achievement marks a significant milestone in genomic medicine.
The personalized therapy was uniquely developed in just six months for an infant suffering from a life-threatening rare metabolic disorder. This rapid development showcases advanced capabilities in gene editing and mRNA technology.
This operational milestone underscores Aldevron's expertise in producing high-quality DNA, RNA, and protein components for advanced therapies. It highlights Danaher's commitment to accelerating the development of revolutionary, life-saving treatments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.